Sign in
Taking people in United StatesPhase 1/2

Tests a live bacteria product with pembrolizumab in advanced cancers

Tests CJRB-101 with pembrolizumab in adults with advanced lung, head and neck, or skin cancer.

Key facts

Who runs it
CJ Bioscience, Inc.
Where
Irvine and Pittsburgh, United StatesSee the 2 sitesAlso in 1 other country, 2 sites
Trial code
Registry title
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Status
Recruiting
Phase
Phase 1/2
People taking part
160 people, planned
Started
11 Sept 2023
Expected to end
Oct 2027
Type of study
Interventional
Treatments tested
  • CJRB-101
  • Pembrolizumab injection
Record updated
20 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic lung cancer (NSCLC), head and neck cancer (HNSCC) or melanoma. They get CJRB-101 capsules together with pembrolizumab.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Locally advanced unresectable or metastatic NSCLC, HNSCC or melanoma, with at least 1 measurable tumor lesion that has not been resected, biopsied or irradiated before enrollment.
Earlier treatment
Two groups can join. Group 1 has not had immune checkpoint inhibitor (ICI) treatment and has had no prior systemic treatment for the metastatic tumor. Group 2 has had at least 2 cycles of anti-PD-(L)1 therapy, got worse afterwards, and has had less than three lines of systemic therapy for the metastatic tumor.
Biomarker or test result
For people new to ICI treatment: NSCLC needs no EGFR or ALK changes and PD-L1 TPS ≥50%. HNSCC needs PD-L1 CPS ≥20. Melanoma has no PD-L1 or BRAF V600 requirement.

Main reasons for not taking part

  • NSCLC with EGFR or ALK changes, or nasopharyngeal head and neck cancer
  • Uncontrolled or untreated brain metastasis or leptomeningeal disease
  • Active autoimmune disease treated with systemic therapy in the past 2 years
  • Prior fecal transplant, or organ transplant needing immunosuppressive therapy
  • Pregnant or breastfeeding, or known HIV infection

The registry criteria, word for word

Show all 39 criteriaShow less

Who can take part

  • Willing and able to provide informed consent
  • ≥18 years of age at the time of signing the informed consent form
  • Pathologically documented histological or cytological evidence of NSCLC, HNSCC, or melanoma
  • Has at least 1 measurable target lesion per RECIST v1.1 that has not been resected/biopsied/or irradiated before enrollment in the study
  • Diagnosis of locally advanced unresectable or metastatic NSCLC, HNSCC, or melanoma in subjects who are ICI treatment-naive or relapsed/refractory, including PD-1/PD-L1 inhibitors
  • ICI treatment-naive subjects must meet the following criteria:; NSCLC: Subjects with metastatic or with unresectable, recurrent NSCLC whose tumors must have no EGFR or ALK genomic aberrations and express PD-L1 [TPS≥50%]; HNSCC: Subjects with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [CPS ≥20]; Melanoma: Irrespective of PD-L1 result and BRAF V600 mutation; Subjects has not received prior systemic treatment for their metastatic tumor. Subjects who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 6 months before the development of metastatic disease
  • ICI treatment-refractory subjects as defined by the following criteria:; Has received at least 2 cycles of anti-PD-(L)1 therapy either as monotherapy or in combination; Has demonstrated disease progression after ICI treatment by RECIST v1.1; Has received less than three lines of systemic therapy for metastatic tumor
  • ECOG performance status of 0 or 1
  • Be willing to provide archival tissue or fresh biopsy
  • Have adequate organ function
  • All Grade 3 or greater AEs resolved earlier to Grade 2 or less

Who cannot take part

  • For ICI refractory/relapsed subjects: Immune related AEs ≥Grade 3 that led to discontinuation of prior immune-modulatory agents including PD-1/PD-L1 inhibitors
  • Received a fecal transplant
  • Concurrent participation in another interventional clinical study or use of another investigational agent within 30 days of study consent
  • Contraindication to IV contrast that cannot be managed with pre-medication
  • Has received a live vaccine within 4 weeks of start of the study treatment
  • Diagnosis of prior immunodeficiency or organ transplant requiring immunosuppressive therapy
  • Has received whole blood transfusion, blood component transfusion, or colony stimulating factors within 1 week prior to the 1st dose of study treatment
  • Has active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis requiring treatment with systemic steroids
  • Infection requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days before study treatment (Note: Antiviral therapy is permitted for subjects with chronic HBV or HCV infection)
  • Untreated chronic hepatitis B or chronic HBV carriers with HBV DNA>500 IU/mL (or >2500 copies/mL) at screening (Note: Inactive hepatitis B surface antigen (HbsAg) carriers, treated and stable hepatitis B (HBV DNA < 500 IU/mL or < 2500 copies/mL) can be enrolled. Subjects with detectable HbsAg or detectable HBV DNA should be managed per treatment guidelines. Subjects receiving antivirals at screening should have been treated for > 2 weeks before study treatment.)
  • With active hepatitis C (Note: Subjects with a negative HCV antibody test at screening or positive HCV antibody test followed by a negative HCV ribonucleic acid (RNA) test at screening are eligible. The HCV RNA test will be performed only for subjects testing positive for HCV antibody. Subjects receiving antivirals at screening should have been treated for > 2 weeks before study treatment.)
  • Major surgery for any reason, except diagnostic biopsy, within 4 weeks of study informed consent and or if the subject has not fully recovered from the surgery within 4 weeks of informed consent
  • Known active intravenous drug or alcohol abuse or use of other drugs of abuse
  • With uncontrolled or untreated brain metastasis or leptomeningeal disease
  • Active autoimmune disease that has required systemic treatment in the past 2 years
  • Have allergy to clindamycin, erythromycin, and ampicillin
  • Known history of HIV infection
  • History of active inflammatory bowel disease with diarrhea believed to be caused by active inflammatory bowel disease in the past 12 months
  • History of major gastrointestinal surgery
  • Currently active, clinically significant cardiovascular disease
  • Cancer type and genomic tumor aberrations:; NSCLC subjects with EGFR or ALK genomic tumor aberrations; HNSCC subjects with nasopharyngeal cancer
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial
  • Female subjects who are pregnant or breastfeeding
  • Male subjects who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy
  • Has a known inability for oral intake of capsules
  • In the judgment of the investigator, subjects unlikely to comply with study procedures, restrictions and requirements
  • Has signs and symptoms of colitis at screening
  • Has any contraindication as mentioned in the recent Keytruda, Highlights of Prescribing Information (pembrolizumab)

Where in United States

Also in 1 other country, 2 sites

  • University of California, IrvineIrvine, United StatesContact: Misako Nagasaka, MD, PhDTaking people
  • University of PittsburghPittsburgh, United StatesContact: Diwakar Davar, MDTaking people

About the trial

What the trial wants to find out

Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the unmet medical needs of low response rate and refractoriness to immune checkpoint inhibitors typically observed in this subject population by performing assessments of response, dose limiting toxicities, pharmacodynamic, and the effect on microbiome biomarkers at different dose levels of CJRB-101 combined with pembrolizumab.

The group in the trial

  • CJRB-101 with pembrolizumabTreatment being tested

    Phase 1 includes patients with selected types of advanced or metastatic cancers. Patients will be given with either low or high dose levels of CJRB-101 in combination with pembrolizumab. Phase 2 includes patients with selected types of advanced or metastatic cancers. Patients will be given with the CJRB-101 dose selected from Phase 1 in combination with pembrolizumab.

    Treatment: CJRB-101 and Pembrolizumab injection

Results explained

A paper that names this trial, explained in plain words.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Plain-language title
Tests a live bacteria product with pembrolizumab in advanced cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
20 December 2024